Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423643 · ClinicalTrials.gov registry record
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 1,250
- Enrollment target
NCT01423643: Completed study, sponsored by Johns Hopkins University.
NCT01423643 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 1,250 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01423643 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 1,250 participants
- Enrollment target
Study Summary
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV). The investigators study liver disease progression in a cohort of dually infected persons according to the success of ART.
Primary Outcome
Liver histologic fibrosis stage (Ishak 0 - 6)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2001-03 |
| Est. Completion | 2015-10 |
What the finished NCT01423643 record still lists
NCT01423643 is an observational study that tracks outcomes without assigning an intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01423643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01423643 about?
NCT01423643 is a clinical study titled "HCV/HIV Coinfection: Antiviral Therapy and Fibrosis". The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV). The investigators study liver disease progression in a cohort of dually infected persons according to the success of ...
What is the current status of trial NCT01423643?
This trial is currently completed. The enrollment target is 1,250 participants. The study started on 2001-03. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT01423643?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia